AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Healthcare Realty Trust Incorporated
Video analysis: HR
All videosNo video analysis for this stock yet. Request one from our team.
News: HR
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTIN
Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo's ENHERTUÂ (fam-trastuzumab deruxtecan-nxki) demonstrated a stat
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/url] that updated data, including overall survival (OS), from
Healthcare Realty Trust (HR) Upgraded to Buy: What Does It Mean for the Stock?
Healthcare Realty Trust (HR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
AstraZeneca's ETCAMAHÂ (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been appro
Bears are Losing Control Over Healthcare Realty Trust (HR), Here's Why It's a 'Buy' Now
Healthcare Realty Trust (HR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
After Plunging 7.0% in 4 Weeks, Here's Why the Trend Might Reverse for Healthcare Realty Trust (HR)
Healthcare Realty Trust (HR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Healthcare Realty Trust Q2 Earnings Call Highlights
Healthcare Realty Trust NYSE: HR reported second-quarter results marked by higher occupancy, leasing activity, same-store net operating income growth and an increase to its full-year funds-from-operations outlook. Management said the company's performance continues to run ahead of objectives outlined in its strategic plan one year ago.
Healthcare Realty Trust Incorporated (HR) Q2 2026 Earnings Call Transcript
Healthcare Realty Trust Incorporated (HR) Q2 2026 Earnings Call Transcript
Similar companies
-
CareTrust REIT, Inc.
CTRE
·
New York Stock Exchange
Compare
-
American Healthcare REIT, Inc.
AHR
·
New York Stock Exchange
Compare
-
First Industrial Realty Trust, Inc.
FR
·
New York Stock Exchange
Compare
-
Terreno Realty Corporation
TRNO
·
New York Stock Exchange
Compare
-
Starwood Property Trust, Inc.
STWD
·
New York Stock Exchange
Compare
-
STAG Industrial, Inc.
STAG
·
New York Stock Exchange
Compare